Article

Abbreviated Radiotherapy Shows Promise in Prostate Cancer

Dramatically condensing radiation treatment for early prostate cancer into just 5 fractions produces good results without much toxicity, an early-phase study suggested. The hypofractionated schedule resulted in 99% biochemical and pathological control and only 1% experienced mild radiation side effects at 3 years, D. Andrew Loblaw, MD, of Sunnybrook Health Sciences Center in Toronto, and colleagues found.

Acute toxicity topped out at 1 case of grade 3 genitourinary problems among 83 patients treated, they reported here at the Genitourinary Cancers Symposium.

"That's a huge deal. Normal dosing is 40 to 45 fractions," Nicholas J. Vogelzang, MD, medical director of the developmental therapeutics committee of US Oncology, told MedPage Today. "Using accelerated hypofractionation, you can get what appear to be identical outcomes."

Not only would the once-weekly schedule with a total of only 5 radiation treatments used in the study be more convenient for patients, but it would likely substantially drop overall radiation costs, Vogelzang predicted.

Read more at: http://www.medpagetoday.com/MeetingCoverage/MGUCS/31020

Source: MedPage Today

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Related Content
CH LogoCenter for Biosimilars Logo